|
|
|
Agenda
The two parallel tracks of Screening Europe will also be held in parallel to MedChem and ADMET Europe sessions: Sessions Overview
Day 1 – February 19
Track A
|
8:30 |
Registration
|
|
9:30 |
Novel High-Throughput Platforms
Chaired by Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Centre
|
|
9:35 |
High Content Screening of Human ES Cells Using Laser
Scanning Confocal Microscopy
Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Centre
The group has successfully developed and validated a high content assay to screen for novel modulators of human embryonic stem cells; these could either help maintain self renewal status or induce differentiation to various specialized cell types.
|
|
10:05 |
Modern Approaches for an Old Problem: High-Throughput
Screening and Compound Profiling of Proteases
Lorenz Mayr, Executive Director, Novartis Pharma
State-of-the-art HTS and uHTS processes, modern readout
technologies, miniaturized screening and profiling, label-free
detection for hit validation, lead-optimisation support, process driven organisational structure.
|
|
10:35 |
Coffee break and networking in exhibition hall
|
|
11:20 |
Transcription-Guided Discovery: Using Changes in Gene
Expression to Guide All Stages of Drug Development
Reinhard Ebner, Principal Scientist, Avalon Pharmaceuticals
Summarizes how an unbiased chemical genomics approach can result in fast and rational selection of hits and leads, support decisions about which compounds to advance toward clinical trials, and facilitate clinical development through identification of efficacy, stratification or response markers.
|
|
11:50 |
Advances in Docking and Structure Based Compound
Screening
Ruben Abagyan, Professor, Department of Molecular Biology, Scripps Research Institute
The presented docking and scoring protocol has a remarkable
capacity of recognizing its strong binders from thousands to hundreds of thousands of compounds.
|
|
12:20 |
Lunch & networking in exhibition hall
|
|
12:50
|
 GE Healthcare Workshop: Applications of Microcarrier Cultured Cryopreserved Cells in Screening Assays for GPCRs
|
|
13:20 |
Poster viewing
|
|
14:00 |
Oncology Target Screening
Chaired by Steven Smith, Professor of Molecular Science, City of Hope
|
|
14:05 |
qPCR and Methylation Sensitive qPCR Performance at Sites of
Stable non-B DNA Structure in Human Gene Promoters
Steven Smith, Professor of Molecular Science, City of Hope
Non-B DNA structures can be detected in the promoter regions of
living cells. The simultaneous analysis of information on secondary
structure and DNA methylation described here may provide a new
tool in cancer screening.
|
|
14:35 |
Identification of Therapeutic Targets Associated with PI3K/Akt Signalling Through High Content Loss-of-Function Screenings
Fábian Zanella de Sá, PhD Student, Assay Development Group, Experimental Therapeutics Program, Spanish National Cancer Centre - CNIO
RNAi knockdown techniques combined with automated fluorescence imaging a allowed the discovery of novel components of the PI3K/Akt cascade.
|
|
15:05 |
Coffee break and networking in exhibition hall
|
|
15:50 |
Using 3-D Culture Models to Screen for Compounds that
Induce Apoptosis of Cancer Cells
Stig Linder, Professor, Group Leader, Karolinska Institute
A procedure, where multicellular spheroids are used to screen for
compounds that induce tumour cell apoptosis, was developed by the group. This procedure is attractive for secondary screening of hits from larger cell based screens and its advantages will be described.
|
|
16:20 |
speaker to be announced
|
|
16:50 |
Development of Hsp90 Inhibitors for Multiple Cancers
Rob Howes, Head of Screening and Assay Technologies, Vernalis
Hsp90 inhibition has been promoted as degradation mechanism of
oncogenic proteins. A streamlined screening cascade to rapidly assess compounds for their ability to bind to Hsp90 and inhibit its function in vitro and in cell based assays will be presented.
|
|
17:20 |
Drinks reception compliments of HTScreening.net |
Track B
|
8:30 |
Registration
|
|
9:30 |
Screening Automation and Miniaturisation
Chaired by Alf Månsson, Associate Professor, University of Kalmar
|
|
9:35 |
Molecular Motor Powered Lab-on-a-Chip Devices for Highly Parallel and Miniaturized Drug Screening
Alf Månsson, Associate Professor, University of Kalmar
The work concerns a paradigmatically novel lab-on-a-chip concept with molecular motor powered nanoscale transportation systems, e.g. for highly parallel and miniaturized drug screening.
|
|
10:05 |
High-Throughput siRNA Transfection Applying a 384-Multichannel Pipetting Head Avoiding Disposable Tips
Eberhard Krauß, Head, HT-Technology Development Studio, Max Planck Institute of Molecular Cell Biology & Genetics
For numerous reagents and cell lines the group elaborated automated siRNA transfection protocols applying a 384- tefloncoated multichannel pipetting head. Further, they established washing protocols to avoid use of disposable tips completely. The group achieves 50,000 samples throughput per day.
|
|
10:35 |
Coffee break and networking in exhibition hall
|
|
11:20 |
A Flexible HCA System for the Automatic Image Analysis and Interpretation of Cell Images
Petra Perner, Director, Institute of Computer Vision and Applied Computer Sciences, IBaI
The presentation will include Automatic Image-Analysis, Automatic Image-Interpretation, Mass Data-Analysis of Images, Drug Screening, Automatic Cell-Image Analysis and Automatic Cell-Image Tracking.
|
|
11:50 |
The Industrialisation of 1536 Well Format High Throughput
Screening for Modulators of G Protein-Coupled Receptors
Stuart Baddeley, Team Leader, Biochemistry Hit Identification,
GlaxoSmithKline
This presentation will describe the industrialization of screening to
identify lead molecules for GPCRs. Assay formats including ligand
binding assays, cAMP detection, reporter gene assays and aequorin have been successfully transferred to 1536 well format to enable rapid hit identification.
|
|
12:20 |
Lunch & networking in exhibition hall
|
|
12:50 |
GE Healthcare Workshop: Applications of Microcarrier Cultured Cryopreserved Cells in Screening Assays for GPCRs
|
|
13:20 |
Poster viewing
|
|
14:00 |
GPCR’s
Chaired by Torsten Schöneberg, Professor of Molecular Biochemistry and Endocrinology, University of Leipzig
|
|
14:05 |
Effector-Dependent Signaling Profiles of GPCR Ligands in
Recombinant and Primary Cells
Evi Kostenis, Head of Department, Director of Institute, University
of Bonn
GPCRs represent an important class of molecular targets for development of therapeutic agents. Accumulating evidence suggests, that efficacy of such agents does not only depend on the ligand/receptor couple but also on the type of signaling effector. Selected examples will be presented.
|
|
14:35 |
Emerging GPCR Assay Technologies for Drug Discovery
Sandra Siehler, Research Investigator II, Novartis Institutes for
BioMedical Research
Novel fluorescent technologies applicable for GPCR drug identification will be explained. The presentation will focus on discovery of signaling mechanisms, GPCR-mediated activation of ERK1/2, and modulation of the G12/13-signaling pathway.
|
|
15:05 |
Coffee break and networking in exhibition hall
|
|
15:50 |
Novel Concepts in GPCR Drug Discovery
Miranda van der Lee, Senior Scientist Molecular Pharmacology-GPCR section, NV Organon, a part of Schering-Plough Corporation
Emerging concepts of GPCR function, such as allosterism,
internalization and dimerization, provide entirely new opportunities for drug discovery. The use of cryopreserved cells increases the flexibility of cell-based drug discovery and improves assay data quality.
|
|
16:20 |
Unveiling Drug Selectivity Via Functional Profiling and a Multi-Prong Approach to Hit Validation Using Chemiscreen™ GPCR Cell Lines
Blaine N. Armbruster, Product Manager - GPCR Drug Discovery, Millipore
A key challenge in drug discovery is how to quickly screen compound libraries and subsequently validate the effectiveness and selectivity of resulting hits. A simple screening platform that is amenable to functional primary screening, selectivity profiling and secondary readouts will be presented.
|
|
16:50 |
Functional Characterization of GPCR in the Light of Evolution
Torsten Schöneberg, Professor of Molecular Biochemistry and
Endocrinology, Institute of Biochemistry, Medical Faculty, University of Leipzig
Mined evolution as an additional source of structural information may be helpful in interpreting the functional relevance of orphan GPCR, in directing mutagenesis studies and receptor modelling. The talk will present examples to demonstrate the power of evolutionary approaches in GPCR research.
|
|
17:20 |
Drinks reception compliments of HTScreening.net
|
Day 2 – February 20
Track A
|
8:00 |
 TTP Labtech Workshop: Achieving Acurate Nanolitre Pipetting for Miniaturising Serial Dilutions and Assay-Ready Plates
|
|
9:30 |
Label-Free Detection
Chaired by Oliver Nayler, Director, Head Molecular Biology, Actelion Pharmaceuticals
|
| 9:35 |
Cell-Impedance Measurements of GPCR Modulators –
Characterization of Signalling Pathways in Non-Recombinant
Cells
Oliver Nayler, Director, Head Molecular Biology, Actelion Pharmaceuticals
The application of cell-electrode impedance measurements as a noninvasive and label-free cell based assay to study cell signalling of the natural ligand or small molecular weight GPCR modulators will be discussed. Case studies comparing this novel technology with standard assay systems will be shown.
|
|
10:05 |
A Method for Label-Free Screening in Fragment-Based Drug Design
Andrei Zhukov, Development Scientist, GE Healthcare Bio-Sciences
A sensitive screening method based on label-free (SPR) detection of binding, which accommodates simultaneous analysis against four different targets will be presented and illustrated.
|
| 10:35 |
Coffee break and networking
|
|
11:20 |
Label-Free Screening of Fragment Libraries by SPR Imaging
Andrea Noeren-Mueller, Research Scientist, Graffinity Pharmaceuticals
The audience is introduced to SPR imaging of chemical microarrays
as a powerful tool for label-free and function blind screening. The
technology is particularly suited for fragment based drug discovery.
|
| 11:50 |
A Comparison of Cell-Based Label-Free Assay Tools
Lisa Minor, Principal Scientist, Johnson & Johnson
Label-free technologies based on electrical impedance or refractive index technologies will be described and compared. Their application to cell-based assays using the G protein coupled receptor, Urotensin II, will be described as an example.
|
|
12:20 |
Lunch & networking in exhibition hall
|
|
13:00 |
Poster viewing
|
|
13:30 |
Protein Kinases
|
|
13:35 |
Neglected Diseases: Building a Lead Discovery Engine
Dominique Perrin, Group Leader, Merck Serono International
Merck Serono has been engaged since 2004 in a collaborative program with the WHO and academic partners on neglected diseases. Over the years a discovery engine was built. Case studies of phosphatase, kinase and protease screens will be presented.
|
|
14:05 |
Coffee break and networking in exhibition hall
|
|
14:35 |
The Role of the Host - Identification and Characterization of
Host Cell Factors Involved in Infection Processes
Nikolaus Machuy, Head of Screening Facility, Max Planck Institute for Infection Biology
Pathogens cause a broad range of severe diseases. The group aim
towards an understanding of the host pathogen interactions and
underlying host cell responses. In order to identify host factors
affecting infection processes, they exploit RNA interference to perform loss-of-function screens.
|
|
15:05 |
Receptor Selection and Amplification Technology: A Unique, Powerful Screening Platform for Drug Discovery
Fabrice Piu, Director Chemical Genomics, ACADIA Pharmaceuticals
A homogeneous functional cell-based assay that has been successfully applied to various genomic targets from receptors to intracellular signaling molecules. Unique features make it particularly efficient in identifying surrogate ligands for constitutively activated receptors, peptide GPCRs and orphan receptors.
|
|
15:35 |
Close of conference
|
Track B
|
8:00 |
TTP Labtech Workshop: Achieving Acurate Nanolitre Pipetting for Miniaturising Serial Dilutions and Assay-Ready Plates
|
|
9:00 |
Cell-Based Assays and Assay Development
Chaired by Christer Wingren, Associate Professor / Lecturer, Lund University
|
|
9:05 |
Design of Recombinant Antibody Microarrays for High-
Throughput Proteomics
Christer Wingren, Associate Professor / Lecturer, Lund University
Design of recombinant antibody microarray technology platforms for high-content screening of clinical samples. The optimized assay setups and some key applications thereof will be presented.
|
|
9:35 |
Point-of-Care Diagnosis Through Impedimetric Detection of a
Biomarker in Whole Blood
Vincent Auger, Research Fellow and Coordinator of the European DVT-IMP Project, University of Teesside
A point-of-care medical diagnostic device is being developed to
decrease the time necessary before the treatment of patients
suspected of deep vein thrombosis (DVT) and pulmonary embolism
(PE). The device is being developed through impedimetric detection of a D-dimer marker present in blood with sample transport and detection being carried out in a microfluidic cartridge system.
|
|
10:05 |
Adult Epithelial Stem Cell Assay Development
Patricia Hurley, Principal Scientist, Novel Therapies Division, Epistem Holdings
Epistem is discovering the key regulators of adult epithelial stem cells and developing protein therapeutics that control cell production in the areas of oncology, and epithelial diseases. Key elements from our discovery platform will be presented.
|
|
10:35 |
Coffee break and networking in exhibition hall
|
|
11:20 |
Slide-Based Miniaturized Microtiter Plate for ELISA and Cellbased Assays
Namyong Kim, Team Leader and Senior Research Scientist, Institute of Bioengineering and Nanotechnology
The miniaturized microtiter platform is expected to enable convenient and straightforward miniaturization of many complex assays such as ELISA and cell-staining assays, leading to the accelerated progress of life sciences and drug discovery research.
|
|
11:50 |
Phenotypic Cell-Based Assay Development for HTS for Anti-
Infectious Diseases Drugs Identification
Thierry Christophe, Head of Screening Technologies and
Pharmacology, Pasteur Institute Korea
The group has developed a High Content Screening assay using
either fluorescence or automated confocal microscopy for infectious disease such as HIV or M. tuberculosis infection. The results of this development and large scale screens will be presented and discussed.
|
| 12:20 |
Lunch & networking in exhibition hall
|
|
13:00 |
Poster viewing
|
|
16:00 |
Close of conference
|
|